Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).
Publication
, Conference
Waring, PM; Desai, J; Rudzki, ZB; Wilson, K; Gebski, V; Nott, LM; Karapetis, CS; Khasraw, M; Underhill, C; Pavlakis, N; Chantrill, LA ...
Published in: Journal of Clinical Oncology
May 20, 2014
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
e14536 / e14536
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Waring, P. M., Desai, J., Rudzki, Z. B., Wilson, K., Gebski, V., Nott, L. M., … Segelov, E. (2014). Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC). In Journal of Clinical Oncology (Vol. 32, pp. e14536–e14536). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.e14536
Waring, Paul Michael, Jayesh Desai, Zbigniew Barney Rudzki, Kate Wilson, Val Gebski, Louise M. Nott, Christos Stelios Karapetis, et al. “Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, 32:e14536–e14536. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e14536.
Waring PM, Desai J, Rudzki ZB, Wilson K, Gebski V, Nott LM, et al. Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. e14536–e14536.
Waring, Paul Michael, et al. “Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. e14536–e14536. Crossref, doi:10.1200/jco.2014.32.15_suppl.e14536.
Waring PM, Desai J, Rudzki ZB, Wilson K, Gebski V, Nott LM, Karapetis CS, Khasraw M, Underhill C, Pavlakis N, Chantrill LA, Shapiro JD, Segelov E. Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. e14536–e14536.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
e14536 / e14536
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences